News

Prosecutors: Elizabeth Holmes used fake Pfizer endorsement of Theranos tech to get Walgreens deal

In testimony, scientist says he recommended pharmaceutical giant stay away from partnership

Elizabeth Holmes, founder and CEO of Theranos, arrives at the federal courthouse with her mother, Noel Holmes, left, and her husband, Billy Evans, right, in San Jose on Oct. 1, 2021. Courtesy Harika Maddala/Bay City News.

Prosecutors via testimony Friday backed up their claim in their opening statement that Elizabeth Holmes, founder and CEO of Theranos, sent a forged report to Walgreens supposedly showing that pharmaceutical giant Pfizer Inc. had endorsed and validated the now-defunct blood testing company's technology.

Holmes is on trial in federal court in San Jose for 12 counts of wire fraud and conspiracy to commit wire fraud, facing up to 20 years in prison and $3 million in fines if she is convicted.

The tale unfolded on Friday with the testimony of Shane Weber, a scientist with Pfizer who evaluated Theranos' technology in 2008 and wrote a report recommending that the pharmaceutical company stay away from any partnership with Theranos.

Pfizer was looking for tools that would facilitate patient intake for clinical trials. Weber investigated a Theranos-prepared oncology study in which the company described its own systems as showing "superior performance" and having "excellent" accuracy, performing well when compared to "commercially available gold standards."

Weber concluded that Theranos "does not at this time have any diagnostic or clinical interest to Pfizer," peppering his report with criticisms of the company's lack of transparency.

What's local journalism worth to you?

Support Mountain View Online for as little as $5/month.

Join

The report described Theranos as providing "noninformative, tangential, deflective or evasive answers to a written set of technical due diligence questions." Theranos, Weber said, "unconvincingly argues the case for having accomplished tasks of interest to Pfizer."

Referring to the Theranos oncology study, Weber reported that "the nine conclusions in their summary document are not believable based on the information provided."

But the kicker came when prosecutors showed Weber a new version of the original Theranos oncology study — the "summary document," as Weber called it — now with a Pfizer logo slapped on it. The new version was attached to an email that Holmes sent to Walgreens in 2010 as part of discussions about the use of Theranos technology in Walgreens stores, with the subject line "Pfizer Theranos System Validation Final Report." The clear implication of the email and attachment was that Pfizer had put its stamp of approval on the glowing internal Theranos report.

Asked whether it was fair to say that Pfizer had endorsed Theranos's technology or "comprehensively validated" it, Weber responded "No." In fact, Pfizer came to "the opposite conclusion."

Weber was followed by John Bryan Tolbert, vice president of finance for a company that invested $2 million in Theranos in 2006 and another $5 million on Jan. 31, 2013.

Stay informed

Get the latest local news and information sent straight to your inbox.

Stay informed

Get the latest local news and information sent straight to your inbox.

Tolbert taped a Theranos shareholder call in late 2013 in which Holmes referred to the company's "contracts with the military" and touted the quick turnaround of patient samples because of the on-site pharmacy testing available with the company's Edison devices.

She told investors that Theranos was "able to run any kind of test" based on a blood sample collected by a fingerstick test rather than the "big tubes of blood" traditionally required. She also described plans to quickly scale up the Theranos retail presence to 8,000 locations from the dozen or so in place at the time.

Tolbert testified that the technological advantages and plans to use new money to expand as described by Holmes in the call were "significant" in his company's decision to put more money into Theranos 11 days later.

Earlier in the day, the start of the trial was delayed as U.S. District Judge Edward Davila and lawyers met in the judge's chambers to deal with yet another email from one of the jurors. Returning to the courtroom, Davila said, without elaboration, that he had dismissed Juror No. 5 for good cause and replaced her with an alternate.

The switch leaves the gender composition of the jury at eight men and four women.

Two jurors were dismissed earlier in the trial, meaning that there are just two alternates left, with at least six weeks of trial to go.

If the jury runs out of alternates and gets below the required 12 members before starting deliberations, both the prosecution and the defense would have to agree to accept a verdict by a smaller panel of jurors. Without such an agreement, the case would result in a mistrial, leaving prosecutors to decide whether to try again.

A front row seat to local high school sports.

Check out our new newsletter, the Playbook.

Follow Mountain View Voice Online on Twitter @mvvoice, Facebook and on Instagram @mvvoice for breaking news, local events, photos, videos and more.

Get uninterrupted access to important local crime news. Become a member today.

Prosecutors: Elizabeth Holmes used fake Pfizer endorsement of Theranos tech to get Walgreens deal

In testimony, scientist says he recommended pharmaceutical giant stay away from partnership

by /

Uploaded: Tue, Oct 26, 2021, 11:29 am

Prosecutors via testimony Friday backed up their claim in their opening statement that Elizabeth Holmes, founder and CEO of Theranos, sent a forged report to Walgreens supposedly showing that pharmaceutical giant Pfizer Inc. had endorsed and validated the now-defunct blood testing company's technology.

Holmes is on trial in federal court in San Jose for 12 counts of wire fraud and conspiracy to commit wire fraud, facing up to 20 years in prison and $3 million in fines if she is convicted.

The tale unfolded on Friday with the testimony of Shane Weber, a scientist with Pfizer who evaluated Theranos' technology in 2008 and wrote a report recommending that the pharmaceutical company stay away from any partnership with Theranos.

Pfizer was looking for tools that would facilitate patient intake for clinical trials. Weber investigated a Theranos-prepared oncology study in which the company described its own systems as showing "superior performance" and having "excellent" accuracy, performing well when compared to "commercially available gold standards."

Weber concluded that Theranos "does not at this time have any diagnostic or clinical interest to Pfizer," peppering his report with criticisms of the company's lack of transparency.

The report described Theranos as providing "noninformative, tangential, deflective or evasive answers to a written set of technical due diligence questions." Theranos, Weber said, "unconvincingly argues the case for having accomplished tasks of interest to Pfizer."

Referring to the Theranos oncology study, Weber reported that "the nine conclusions in their summary document are not believable based on the information provided."

But the kicker came when prosecutors showed Weber a new version of the original Theranos oncology study — the "summary document," as Weber called it — now with a Pfizer logo slapped on it. The new version was attached to an email that Holmes sent to Walgreens in 2010 as part of discussions about the use of Theranos technology in Walgreens stores, with the subject line "Pfizer Theranos System Validation Final Report." The clear implication of the email and attachment was that Pfizer had put its stamp of approval on the glowing internal Theranos report.

Asked whether it was fair to say that Pfizer had endorsed Theranos's technology or "comprehensively validated" it, Weber responded "No." In fact, Pfizer came to "the opposite conclusion."

Weber was followed by John Bryan Tolbert, vice president of finance for a company that invested $2 million in Theranos in 2006 and another $5 million on Jan. 31, 2013.

Tolbert taped a Theranos shareholder call in late 2013 in which Holmes referred to the company's "contracts with the military" and touted the quick turnaround of patient samples because of the on-site pharmacy testing available with the company's Edison devices.

She told investors that Theranos was "able to run any kind of test" based on a blood sample collected by a fingerstick test rather than the "big tubes of blood" traditionally required. She also described plans to quickly scale up the Theranos retail presence to 8,000 locations from the dozen or so in place at the time.

Tolbert testified that the technological advantages and plans to use new money to expand as described by Holmes in the call were "significant" in his company's decision to put more money into Theranos 11 days later.

Earlier in the day, the start of the trial was delayed as U.S. District Judge Edward Davila and lawyers met in the judge's chambers to deal with yet another email from one of the jurors. Returning to the courtroom, Davila said, without elaboration, that he had dismissed Juror No. 5 for good cause and replaced her with an alternate.

The switch leaves the gender composition of the jury at eight men and four women.

Two jurors were dismissed earlier in the trial, meaning that there are just two alternates left, with at least six weeks of trial to go.

If the jury runs out of alternates and gets below the required 12 members before starting deliberations, both the prosecution and the defense would have to agree to accept a verdict by a smaller panel of jurors. Without such an agreement, the case would result in a mistrial, leaving prosecutors to decide whether to try again.

Comments

MyOpinion
Registered user
another community
on Oct 26, 2021 at 2:44 pm
MyOpinion, another community
Registered user
on Oct 26, 2021 at 2:44 pm

Holmes needs to go to jail,; for years. Dr. Phyllis Gardner, a Stanford Medical School professor, was skeptical of Theranos at the start. "I just want her convicted," Dr Gardner said of Holmes. "All I want is to see her in an orange jumpsuit with a black turtleneck accent." I hope the jury agrees. Web Link
.


Ok
Registered user
Sylvan Park
on Oct 27, 2021 at 10:33 am
Ok, Sylvan Park
Registered user
on Oct 27, 2021 at 10:33 am

She is not very different from other snake oil (vaporware) salesmen (saleswomen), she just was more successful in the craft of deception.
Trevor Milton next?


Don't miss out on the discussion!
Sign up to be notified of new comments on this topic.

Post a comment

In order to encourage respectful and thoughtful discussion, commenting on stories is available to those who are registered users. If you are already a registered user and the commenting form is not below, you need to log in. If you are not registered, you can do so here.

Please make sure your comments are truthful, on-topic and do not disrespect another poster. Don't be snarky or belittling. All postings are subject to our TERMS OF USE, and may be deleted if deemed inappropriate by our staff.

See our announcement about requiring registration for commenting.